Did you know that not all newly forming tumours persist long-term? If you are intrigued to know what determines the survival of early tumours, check out our latest preprint! @SCICambridge, @PDN_Cambridge. Work led by @GSkrupskelyte and @ @J_E_Rojo 🧵1/8
https://t.co/URP3UNhnzB
Out now @BloodAdvances: "Dual role of signaling pathways in myeloma requires cell type–specific targeting of ligand-receptor interactions." https://t.co/fGiWoinxJp #immunotherapy#immunobiology
Currently at the inaugural two-day @dkfz junior group leader retreat, advancing #cancer research from discovery to therapy. A bright future awaits with highly motivated next-gen scientists at the helm. 🧬🔬 #CancerResearch#NewPI#InnovationInScience@DKTK_
👋 Hello 2024 - introducing nanoranger! 🐍
Are we ready to use @nanopore for tracking clonal evolution with #singlecell#genomics❓
Our manuscript provides vignettes on how, for example by tracking #AML during #immunotherapy
🔥🔥🔥
@NatureComms
https://t.co/om6U0KsS9a
👇1/
I am very excited to share that I'll be joining LMU München/DKTK as a Junior Research Group Leader in Cancer Systems Biology in early 2024. Grateful for this opportunity and looking forward to the scientific journey ahead! @LMU_Muenchen@DKTK_#newPI
If you are interested in being part of the journey, we are looking for 2 PhD students in experimental/ computational cancer biology. Both will focus on understanding the mechanisms of therapy resistance in cancer at the single-cell level.
https://t.co/ZuY82HLg3q
Excited to introduce scKINETICS, an algorithm for joint inference of gene regulatory mechanism and cellular velocity, co-developed by the amazing duo of @CassBurdziak and @juuuulianaar
https://t.co/6WfAtn6HT2